Shanghai CP Guojian Pharmaceutical Co., Ltd. clinical trials
Acquired by 3SBio Inc., Mar 31, 2016 · source ↗
The registry lists 3 studies whose lead sponsor is Shanghai CP Guojian Pharmaceutical Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 26, 2011.
Before and after it joined 3SBio Inc.
- First submitted before Shanghai CP Guojian Pharmaceutical Co., Ltd. became part of 3SBio Inc.
- 3
- First submitted after Shanghai CP Guojian Pharmaceutical Co., Ltd. became part of 3SBio Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Shanghai CP Guojian Pharmaceutical Co., Ltd.3 studies
Something wrong with this grouping? Tell us on the 3SBio Inc. page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All 3SBio Inc. studies →
- Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's LymphomaCompletedNCT01459887Phase 3
Sponsor listed in the registry: Shanghai CP Guojian Pharmaceutical Co., Ltd. · First submitted before Shanghai CP Guojian Pharmaceutical Co., Ltd. became part of 3SBio Inc.
- Study of Cipterbin®, Used Alone or With Vinorelbine in Patients With HER2/Neu-overexpressed Metastatic Breast CancerCompletedNCT01439191Phase 2
Sponsor listed in the registry: Shanghai CP Guojian Pharmaceutical Co., Ltd. · First submitted before Shanghai CP Guojian Pharmaceutical Co., Ltd. became part of 3SBio Inc.
- Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinECompletedNCT01291667
Sponsor listed in the registry: Shanghai CP Guojian Pharmaceutical Co., Ltd. · First submitted before Shanghai CP Guojian Pharmaceutical Co., Ltd. became part of 3SBio Inc.